Truist Financial analyst Nicole Germino assigned a Buy rating to the stock today. The company’s shares closed yesterday at $13.00.

Intellia Therapeutics' innovative gene editing technology could revolutionize medicine, but investors need a strong stomach ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

SAVANNAH, Georgia — There’s no medical treatment for Charcot-Marie-Tooth (CMT) disease, a debilitating neurologic disorder ...

Over the last 7 days, the United States market has risen by 1.2%, contributing to a substantial increase of 35% over the past ...

Discover visionary biotech entrepreneurs, nominated by VCs, who are revolutionizing the industry with innovative, ...

Detailed price information for Vivos Therapeutics Inc (VVOS-Q) from The Globe and Mail including charting and trades.

We reached out to VCs to nominate prominent founders in the industry who are committed to bringing potentially life-changing ...

SentinelOne today announced an extension of its strategic collaboration agreement (SCA) with Amazon Web Services (AWS), designed to deliver generative AI benefits. Under the terms of the agreement, ...

Global consulting firm J.S. Held, proudly celebrating 50 transformative years, joins subsidiary firms, Phoenix Management and Stapleton Group, in highlighting eleven operational improvement, ...

As global markets navigate a complex landscape marked by record highs in key U.S. indices and mixed economic signals, ...

In a perspective article published in Science, Professor Jonathan Rivnay explores next-generation bioelectronic medication.